Back
Compare AU
Compare DGVA vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Dimensional Global Value Trust - Active ETF (DGVA) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DGVA | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 5 | 68 |
Median incremental investment | $6,493.50 | $665.63 |
Median investment frequency | Fortnightly | Monthly |
Median total investment | $2,971.10 | $1,867.64 |
Average age group | 26 - 35 | > 35 |
Key Summary
DGVA | CURE | |
|---|---|---|
Strategy | DGVA.AX was created on 1999-08-27 by Dimensional. The fund's investment portfolio concentrates primarily on large cap equity. The investment objective of the Trust is to provide long-term capital growth by gaining exposure to a diversified portfolio of large Value Companies associated with approved developed markets (excluding Australia). | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 40.41m in AUM and 144 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | JPMorgan Chase & Co (3.04 %) Micron Technology Inc (2.79 %) Exxon Mobil Corp (2.25 %) | Moderna Inc (2.34 %) Roivant Sciences Ltd Ordinary Shares (1.79 %) Arcellx Inc (1.73 %) |
Top 3 industries | Financials (24.31 %) Health Care (22.85 %) Energy (22.16 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (69.68 %) Japan (6.36 %) United Kingdom of Great Britain and Northern Ireland (4.08 %) | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) |
Management fee | 0 % | 0.45 % |
Key Summary
DGVA | CURE | |
|---|---|---|
Issuer | Dimensional | Global X |
Tracking index | S&P Biotechnology Select Industry | |
Asset class | ETF | ETF |
Management fee | 0 % | 0.45 % |
Price | $27.01 | $59.29 |
Size | N/A | $40.390 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 3.09 % | 5.08 % |
Market | ASX | ASX |
First listed date | 18/08/2024 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DGVA | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 5 | 68 |
Median incremental investment | $6,493.50 | $665.63 |
Median investment frequency | Fortnightly | Monthly |
Median total investment | $2,971.10 | $1,867.64 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
DGVA | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DGVA | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |